Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer

The goal of this clinical trial is to learn about the side effects and effectiveness of this novel four-drug combination of chemotherapy (decitabine, selinexor, carboplatin and paclitaxel) on patients with relapsed ovarian, fallopian or primary peritoneal carcinoma. Recently the investigators have found that the combination of decitabine and selinexor, two Food and Drug Administration (FDA) approved chemotherapy agents, may prevent or reverse the development of drug resistance and further the remissions and duration of remissions with standard ovarian cancer chemotherapy with carboplatin and paclitaxel. As decitabine and selinexor are not FDA approved for the participant's cancer, these agents are investigational.

NCT Number	NCT05983276
Lead Sponsor	Loyola University Collaborators: Karyopharm Therapeutics Inc
Conditions	Ovarian Cancer
Enrollment	40 participants
Start Date	2023-11-16
Primary Completion	2030-08-28 (estimated)
Study Completion	2031-08-28 (estimated)
Updated on ClinicalTrials.gov	2024-02-08